Atrial Function in Patients with Breast Cancer After Treatment with Anthracyclines

Abstract Background: Atrial electromechanical delay (EMD) is used to predict atrial fibrillation, measured by echocardiography. Objectives: The aim of this study was to assess atrial EMD and mechanical function after anthracycline-containing chemotherapy. Methods: Fifty-three patients with breast...

Full description

Bibliographic Details
Main Authors: Yalin Tolga Yaylali, Ahmet Saricopur, Mustafa Yurtdas, Hande Senol, Gamze Gokoz-Dogu
Format: Article
Language:English
Published: Sociedade Brasileira de Cardiologia (SBC)
Series:Arquivos Brasileiros de Cardiologia
Subjects:
Online Access:http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0066-782X2016005025103&lng=en&tlng=en
id doaj-0e8bfde6c1764d25b319bfb4fbd407d6
record_format Article
spelling doaj-0e8bfde6c1764d25b319bfb4fbd407d62020-11-24T21:03:20ZengSociedade Brasileira de Cardiologia (SBC)Arquivos Brasileiros de Cardiologia1678-4170010.5935/abc.20160146S0066-782X2016005025103Atrial Function in Patients with Breast Cancer After Treatment with AnthracyclinesYalin Tolga YaylaliAhmet SaricopurMustafa YurtdasHande SenolGamze Gokoz-DoguAbstract Background: Atrial electromechanical delay (EMD) is used to predict atrial fibrillation, measured by echocardiography. Objectives: The aim of this study was to assess atrial EMD and mechanical function after anthracycline-containing chemotherapy. Methods: Fifty-three patients with breast cancer (48 ± 8 years old) who received 240 mg/m2of Adriamycin, 2400 mg/m2 of cyclophosphamide, and 960 mg/m2 of paclitaxel were included in this retrospective study, as were 42 healthy subjects (47 ± 9 years old). Echocardiographic measurements were performed 11 ± 7 months (median 9 months) after treatment with anthracyclines. Results: Left intra-atrial EMD (11.4 ± 6.0 vs. 8.1 ± 4.9, p=0.008) and inter-atrial EMD (19.7 ± 7.4 vs. 14.7 ± 6.5, p=0.001) were prolonged; LA passive emptying volume and fraction were decreased (p=0.0001 and p=0.0001); LA active emptying volume and fraction were increased (p=0.0001 and p=0.0001); Mitral A velocity (0.8 ± 0.2 vs. 0.6 ± 0.2, p=0.0001) and mitral E-wave deceleration time (201.2 ± 35.6 vs. 163.7 ± 21.8, p=0.0001) were increased; Mitral E/A ratio (1.0 ± 0.3 vs. 1.3 ± 0.3, p=0.0001) and mitral Em (0.09 ± 0.03 vs. 0.11 ± 0.03, p=0.001) were decreased; Mitral Am (0.11 ± 0.02 vs. 0.09 ± 0.02, p=0.0001) and mitral E/Em ratio (8.8 ± 3.2 vs. 7.6 ± 2.6, p=0.017) were increased in the patients. Conclusions: In patients with breast cancer after anthracycline therapy: Left intra-atrial, inter-atrial electromechanical intervals were prolonged. Diastolic function was impaired. Impaired left ventricular relaxation and left atrial electrical conduction could be contributing to the development of atrial arrhythmias.http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0066-782X2016005025103&lng=en&tlng=enAtrial FunctionArrhythmias, CardiacUnilateral Breast NeoplasmsAntrhacyclinesDrug TherapyCardiotoxicity
collection DOAJ
language English
format Article
sources DOAJ
author Yalin Tolga Yaylali
Ahmet Saricopur
Mustafa Yurtdas
Hande Senol
Gamze Gokoz-Dogu
spellingShingle Yalin Tolga Yaylali
Ahmet Saricopur
Mustafa Yurtdas
Hande Senol
Gamze Gokoz-Dogu
Atrial Function in Patients with Breast Cancer After Treatment with Anthracyclines
Arquivos Brasileiros de Cardiologia
Atrial Function
Arrhythmias, Cardiac
Unilateral Breast Neoplasms
Antrhacyclines
Drug Therapy
Cardiotoxicity
author_facet Yalin Tolga Yaylali
Ahmet Saricopur
Mustafa Yurtdas
Hande Senol
Gamze Gokoz-Dogu
author_sort Yalin Tolga Yaylali
title Atrial Function in Patients with Breast Cancer After Treatment with Anthracyclines
title_short Atrial Function in Patients with Breast Cancer After Treatment with Anthracyclines
title_full Atrial Function in Patients with Breast Cancer After Treatment with Anthracyclines
title_fullStr Atrial Function in Patients with Breast Cancer After Treatment with Anthracyclines
title_full_unstemmed Atrial Function in Patients with Breast Cancer After Treatment with Anthracyclines
title_sort atrial function in patients with breast cancer after treatment with anthracyclines
publisher Sociedade Brasileira de Cardiologia (SBC)
series Arquivos Brasileiros de Cardiologia
issn 1678-4170
description Abstract Background: Atrial electromechanical delay (EMD) is used to predict atrial fibrillation, measured by echocardiography. Objectives: The aim of this study was to assess atrial EMD and mechanical function after anthracycline-containing chemotherapy. Methods: Fifty-three patients with breast cancer (48 ± 8 years old) who received 240 mg/m2of Adriamycin, 2400 mg/m2 of cyclophosphamide, and 960 mg/m2 of paclitaxel were included in this retrospective study, as were 42 healthy subjects (47 ± 9 years old). Echocardiographic measurements were performed 11 ± 7 months (median 9 months) after treatment with anthracyclines. Results: Left intra-atrial EMD (11.4 ± 6.0 vs. 8.1 ± 4.9, p=0.008) and inter-atrial EMD (19.7 ± 7.4 vs. 14.7 ± 6.5, p=0.001) were prolonged; LA passive emptying volume and fraction were decreased (p=0.0001 and p=0.0001); LA active emptying volume and fraction were increased (p=0.0001 and p=0.0001); Mitral A velocity (0.8 ± 0.2 vs. 0.6 ± 0.2, p=0.0001) and mitral E-wave deceleration time (201.2 ± 35.6 vs. 163.7 ± 21.8, p=0.0001) were increased; Mitral E/A ratio (1.0 ± 0.3 vs. 1.3 ± 0.3, p=0.0001) and mitral Em (0.09 ± 0.03 vs. 0.11 ± 0.03, p=0.001) were decreased; Mitral Am (0.11 ± 0.02 vs. 0.09 ± 0.02, p=0.0001) and mitral E/Em ratio (8.8 ± 3.2 vs. 7.6 ± 2.6, p=0.017) were increased in the patients. Conclusions: In patients with breast cancer after anthracycline therapy: Left intra-atrial, inter-atrial electromechanical intervals were prolonged. Diastolic function was impaired. Impaired left ventricular relaxation and left atrial electrical conduction could be contributing to the development of atrial arrhythmias.
topic Atrial Function
Arrhythmias, Cardiac
Unilateral Breast Neoplasms
Antrhacyclines
Drug Therapy
Cardiotoxicity
url http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0066-782X2016005025103&lng=en&tlng=en
work_keys_str_mv AT yalintolgayaylali atrialfunctioninpatientswithbreastcanceraftertreatmentwithanthracyclines
AT ahmetsaricopur atrialfunctioninpatientswithbreastcanceraftertreatmentwithanthracyclines
AT mustafayurtdas atrialfunctioninpatientswithbreastcanceraftertreatmentwithanthracyclines
AT handesenol atrialfunctioninpatientswithbreastcanceraftertreatmentwithanthracyclines
AT gamzegokozdogu atrialfunctioninpatientswithbreastcanceraftertreatmentwithanthracyclines
_version_ 1716773304656723968